Skip to main content

Articles

Page 13 of 16

  1. Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for acute and extended treatment of symptomatic ...

    Authors: Martin H Prins, Anthonie WA Lensing, Rupert Bauersachs, Bonno van Bellen, Henri Bounameaux, Timothy A Brighton, Alexander T Cohen, Bruce L Davidson, Hervé Decousus, Gary E Raskob, Scott D Berkowitz and Philip S Wells
    Citation: Thrombosis Journal 2013 11:21
  2. Anticoagulation with vitamin K antagonists such as warfarin has historically been used for the long term management of patients with thromboembolic disease. However, these agents have a slow onset of action wh...

    Authors: Faryal Tahir, Haris Riaz, Talha Riaz, Maaz B Badshah, Irbaz B Riaz, Ameer Hamza and Hafsa Mohiuddin
    Citation: Thrombosis Journal 2013 11:18
  3. Behcet’s disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most fre...

    Authors: Hoda Abdel Badaee, Amr Edrees, Sherif Amin, Maher El Amir and Gaafar Ragab
    Citation: Thrombosis Journal 2013 11:17
  4. The incidence of venous thromboembolic disease (VTED) is estimated to be, on average, 1–2 cases per 1,000 individuals per year worldwide. There are few data concerning the incidence rate (IR) of VTED in the Ar...

    Authors: Fernando Javier Vázquez, María Lourdes Posadas-Martínez, Jimena Vicens, Fernán González Bernaldo de Quirós and Diego Hernán Giunta
    Citation: Thrombosis Journal 2013 11:16
  5. New oral anticoagulants (NOAC) are approved for several indications for prophylaxis and treatment of venous thromboembolism and for prevention of embolism in atrial fibrillation at fixed daily doses without ne...

    Authors: Job Harenberg, Sandra Krämer, Shanshan Du, Christel Weiss and Roland Krämer
    Citation: Thrombosis Journal 2013 11:15
  6. Atrial fibrillation (AF) is the most common form of heart arrhythmia and a leading cause of stroke and systemic embolism. Chronic anticoagulation is recommended for preventing those complications. Our study ai...

    Authors: Léon Nshimyumukiza, Julie Duplantie, Mathieu Gagnon, Xavier Douville, Diane Fournier, Carmen Lindsay, Marc Parent, Alain Milot, Yves Giguère, Christian Gagné, François Rousseau and Daniel Reinharz
    Citation: Thrombosis Journal 2013 11:14
  7. Direct oral anticoagulants that target a single coagulation factor have been developed as an alternative to standard therapies with heparin and/or vitamin K antagonists. The purpose of this study was to derive...

    Authors: Martin H Prins and Anthonie WA Lensing
    Citation: Thrombosis Journal 2013 11:13
  8. Microplate-based thrombin generation test (TGT) is widely used as clinical measure of global hemostatic potential and it becomes a useful tool for control of drug potency and quality by drug manufactures. Howe...

    Authors: Yideng Liang, Samuel A Woodle, Alexey M Shibeko, Timothy K Lee and Mikhail V Ovanesov
    Citation: Thrombosis Journal 2013 11:12
  9. Research into new anticoagulants for preventing and treating thromboembolic disorders has focused on targeting single enzymes in the coagulation cascade, particularly Factor Xa and thrombin, inhibition of whic...

    Authors: Meyer Michel Samama, Geneviève Contant, Theodore E Spiro, Elisabeth Perzborn, Lena Le Flem, Céline Guinet, Yves Gourmelin, Gabriele Rohde and Jean-Luc Martinoli
    Citation: Thrombosis Journal 2013 11:11
  10. Unlike traditional anticoagulants, the more recently developed agents rivaroxaban, dabigatran and apixaban target specific factors in the coagulation cascade to attenuate thrombosis. Rivaroxaban and apixaban d...

    Authors: Wolfgang Mueck, Stephan Schwers and Jan Stampfuss
    Citation: Thrombosis Journal 2013 11:10
  11. While the assessment of analytical precision within medical laboratories has received much attention in scientific enquiry, the degree of as well as the sources causing variation between them remains incomplet...

    Authors: Michael Nagler, Lucas M Bachmann, Lorenzo Alberio, Anne Angelillo-Scherrer, Lars M Asmis, Wolfgang Korte, Adriana Mendez, Guido Reber, Hans Stricker, Dimitrios A Tsakiris and Walter A Wuillemin
    Citation: Thrombosis Journal 2013 11:6
  12. Giant left atrium is a condition characterized by huge enlargement of the left atrium with a diameter exceeding 65mm. It is most commonly associated with long standing rheumatic mitral valve disease. We presen...

    Authors: Ahmad K Darwazah and Hamdy El Sayed
    Citation: Thrombosis Journal 2013 11:5
  13. Deep Vein Thrombosis (DVT) is an important cause of morbidity and is the first cause of maternal death after delivery in Western Nations. The risk of venous thromboembolism is present throughout the pregnancy ...

    Authors: Leslie Fiengo, Federico Bucci, Gregorio Patrizi, Domenico Giannotti and Adriano Redler
    Citation: Thrombosis Journal 2013 11:4
  14. Early treatment of disseminated intravascular coagulation (DIC) can be associated with improved patient outcomes. The Japanese Ministry of Health and Welfare (JMHW) and the International Society on Thrombosis ...

    Authors: Takahiro Kato, Takamasa Sakai, Miki Kato, Mao Hagihara, Takaaki Hasegawa, Katsuhiko Matsuura and Takashi Nakagawa
    Citation: Thrombosis Journal 2013 11:3
  15. Previous animal studies by us and others have indicated that catheter-administered plasmin or its des-kringle derivatives may be more appropriate alternatives to plasminogen activators for treating thrombolyti...

    Authors: Xiaotao Lin, Yan Wang, Yanwen Zhang, Bing Huang, James J Lin, Scott J Hallock, Hong Yu, Hongwei Shao, Jing Yan, Bo Huang, Xuejun C Zhang, Wei Cao, Xueming Xu and Xinli Lin
    Citation: Thrombosis Journal 2013 11:2
  16. The aim of the present study was to compare circulating levels of selected prothrombotic markers in patients suffering acute myocardial infarction (AMI) with and without left ventricular (LV) thrombus.

    Authors: Svein Solheim, Ingebjørg Seljeflot, Ketil Lunde, Vibeke Bratseth, Svend Aakhus, Kolbjørn Forfang and Harald Arnesen
    Citation: Thrombosis Journal 2013 11:1
  17. Effective treatment of venous thromboembolism (VTE) strikes a balance between prevention of recurrence and bleeding complications. The current standard of care is heparin followed by a vitamin K antagonist suc...

    Authors: Bastian Hass, Jayne Pooley, Adrian E Harrington, Andreas Clemens and Martin Feuring
    Citation: Thrombosis Journal 2012 10:24
  18. Low Frequency Vibro-Percussion (LFVP) assists clearance of thrombi in catheter systems and when applied to the heart and timed to diastole is known to enhance coronary flow. However LFVP on a clotted coronary ...

    Authors: Andrew Hoffmann and Harjit Gill
    Citation: Thrombosis Journal 2012 10:23
  19. Dual antiplatelet treatment with aspirin and clopidogrel is the antithrombotic treatment recommended after an acute coronary syndrome and/or coronary artery stenting. The evidence for optimal antiplatelet ther...

    Authors: Mila Menozzi, Andrea Rubboli, Antonio Manari, Rossana De Palma and Roberto Grilli
    Citation: Thrombosis Journal 2012 10:22
  20. Hump-nosed pit viper (Genus Hypnale) is a medically important venomous snake in Sri Lanka and Southwestern India which causes significant morbidity and mortality. Envenoming of this snake results in hemostasti...

    Authors: Vijayabala jeevagan, Thashi Chang and Christeine Ariaranee Gnanathasan
    Citation: Thrombosis Journal 2012 10:21
  21. Venous thromboembolism (VTE) is a leading cause of hospital-related deaths worldwide. However, the proportion of patients at risk of VTE who receive appropriate prophylaxis in Egypt is unknown. The ENDORSE stu...

    Authors: Hadi A Goubran, Sherif Sholkamy, Alaa El-Haddad, Alaa Mahmoud, Mounir A Rizkallah and George Sobhy
    Citation: Thrombosis Journal 2012 10:20
  22. Postprandial hyperlipidemia and hyperglycemia have been related to cardiovascular events. Among different underlying mechanisms platelet activation seems to be responsible too. No comparable data between vario...

    Authors: Helmut Sinzinger and Robert Berent
    Citation: Thrombosis Journal 2012 10:19
  23. Computer-assistance and self-monitoring lower the cost and may improve the quality of anticoagulation therapy. The main purpose of this clinical investigation was to use computer-assisted oral anticoagulant th...

    Authors: Rune Skovgaard Rasmussen, Pernille Corell, Poul Madsen and Karsten Overgaard
    Citation: Thrombosis Journal 2012 10:17
  24. Coronary artery disease (CAD) is a major problem worldwide. Atherosclerosis and thrombosis underlying CAD involve multiple cell types. New and useful diagnostic markers are required. MicroRNAs (miRNAs) are a c...

    Authors: Xiao Sun, Man Zhang, Akimasa Sanagawa, Chieko Mori, Shiori Ito, Soichiro Iwaki, Hiroki Satoh and Satoshi Fujii
    Citation: Thrombosis Journal 2012 10:16
  25. Bleeding remains a potentially lethal complication of cardio-pulmonary bypass (CPB) surgery. The purpose of this study was to obtain a better insight into in vitro thrombin generation in the context of CPB.

    Authors: Rose Said, Véronique Regnault, Marie Hacquard, Jean-Pierre Carteaux and Thomas Lecompte
    Citation: Thrombosis Journal 2012 10:15
  26. Venous Thrombo-embolic disease is currently a hot topic especially in the UK. 25,000 patients per year die of Pulmonary Emboli (PE) in the United Kingdom (UK). Hip and knee arthroplasty surgery is associated w...

    Authors: Padmanabhan Subramanian, Shanjitha Kantharuban, Sophie Shilston and Oliver James Pearce
    Citation: Thrombosis Journal 2012 10:14
  27. Obesity, characterised by increased fat mass and is currently regarded as a pro-inflammatory state and often associated with increased risk of cardiovascular diseases (CVD) including Myocardial infarction. The...

    Authors: Karthick Rajendran, Nalini Devarajan, Manohar Ganesan and Malathi Ragunathan
    Citation: Thrombosis Journal 2012 10:13
  28. Cardiovascular disease with disturbances in the haemostatic system, might lead to thrombotic complications with clinical manifestations like acute myocardial infarction (AMI) and stroke. Activation of the coag...

    Authors: Vibeke Bratseth, Alf-Åge Pettersen, Trine B Opstad, Harald Arnesen and Ingebjørg Seljeflot
    Citation: Thrombosis Journal 2012 10:12
  29. Arterial thrombosis triggered by vascular injury is a balance between thrombus growth and thrombus fragmentation (dethrombosis). Unbalance towards thrombus growth can lead to vascular occlusion, downstream isc...

    Authors: Gillian Stephens, Ming He, Connie Wong, Marzena Jurek, Hans-Christian Luedemann, Golnaz Shapurian, Kevin Munnelly, Craig Muir, Pamela B Conley, David R Phillips and Patrick Andre
    Citation: Thrombosis Journal 2012 10:11
  30. The aim was to investigate, whether 5,000 IUaXa/day certoparin lowers the incidence of deep vein thrombosis (DVT) in patients undergoing elective hip replacement surgery vs. 3,000 IUaXa/day. Double-blind, multice...

    Authors: Peter Bramlage, Hans-Christoph Michaelis and Nima Melzer
    Citation: Thrombosis Journal 2012 10:10
  31. There has been a shift towards greater use of neuraxial over general anaesthesia for patients undergoing total hip or knee arthroplasty. Furthermore, suggestions that peripheral nerve block may reduce adverse ...

    Authors: Nadia Rosencher, Herbert Noack, Martin Feuring, Andreas Clemens, Richard J Friedman and Bengt I Eriksson
    Citation: Thrombosis Journal 2012 10:9
  32. Thrombosis and hemostasis related disease have a heavy burden in cardiovascular disease and it is important to have a journal where research into this can be accessed by all.

    Authors: Hugo ten Cate and Yukio Ozaki
    Citation: Thrombosis Journal 2012 10:8
  33. DVT is the main cause of death in hospitalized patients and thromboprophylaxis is the only way to prevent these deaths. International recommendations suggested that active monitoring of DVT/PE prophylaxis can ...

    Authors: Federico Jorge Bottaro, José Manuel Ceresetto, John Emery, Julio Bruetman, Nicholas Emery, Débora Pellegrini, Victoria Pinoni, Gastón Piñeiro, Laura Fox, María Eugenia Orrico, Silvina Palmer, Sebastián Prieto and Eduardo Bullorsky
    Citation: Thrombosis Journal 2012 10:7
  34. The clinical use of Sodium nitroprusside (SNP) may be associated with an alteration of platelet function. The main focus of this study was the effect of SNP on platelet aggregation in the absence or presence o...

    Authors: Hans-Georg Topf, Manfred Rauh, Wolfgang Rascher, Jörg Dötsch and Jens M Klinge
    Citation: Thrombosis Journal 2012 10:6
  35. The number of patients treated with oral anticoagulation (OAC) is increasing and these patients are monitored by International Normalized Ratio (INR). Bleeding complications are common and we speculate if this...

    Authors: Sacha Sølbeck, Sisse R Ostrowski and Pär I Johansson
    Citation: Thrombosis Journal 2012 10:5
  36. A sixty year old male presented with dark urine, symptomatic anaemia and peripheral gangrene following cold exposure. Investigations revealed that he had haemolysis and serological evidence of recent Epstein B...

    Authors: Suneth Karunarathne, Sajitha Weerasinghe, Dumitha Govindapala, Harshini Fernando and Bhaddika Jayaratne
    Citation: Thrombosis Journal 2012 10:4
  37. Patients with heightened platelet reactivity in response to antiplatelet agents are at an increased risk of recurrent ischemic events. However, there is a lack of diagnostic criteria for increased response to ...

    Authors: Raul Altman, Ana J Rivas and Claudio D Gonzalez
    Citation: Thrombosis Journal 2012 10:3
  38. Stachybotrys microspora triprenyl phenols (SMTPs) are a novel family of small molecules that enhance both activation and fibrin-binding of plasminogen. While their effects on fibrinolysis have been characterized

    Authors: Weimin Hu, Ritsuko Narasaki, Naoko Nishimura and Keiji Hasumi
    Citation: Thrombosis Journal 2012 10:2
  39. Effects of nitric oxide (NO) on hemostasis have been studied in various investigational settings, but data regarding inhaled NO on bleeding and platelet function are conflicting. It is not known if inhaled NO ...

    Authors: Brahm Goldstein, James Baldassarre and Joseph N Young
    Citation: Thrombosis Journal 2012 10:1
  40. Venous thromboembolism prophylaxis has been shown to safely and cost-effectively reduce the incidence of thromboembolic events in medical inpatients. However, there is a gap between evidence and medical practi...

    Authors: Agustín Languasco, Mariana Galante, Josefina Marín, Cristina Soler, Cristián Lopez Saubidet and Matías Milberg
    Citation: Thrombosis Journal 2011 9:18
  41. In European countries, low-molecular-weight heparin is generally initiated preoperatively for thromboprophylaxis in hip or knee replacement surgery. The objective of this review is to compare pre- and postoper...

    Authors: Carsten Perka
    Citation: Thrombosis Journal 2011 9:17
  42. To assess the incidence of venous thromboembolism (VTE) and bleeding events with or without thromboprophylaxis and the associated costs in a cohort of medically ill patients in both in-hospital and outpatient ...

    Authors: Li Wang, Nishan Sengupta and Onur Baser
    Citation: Thrombosis Journal 2011 9:15
  43. Patients who receive highly variable doses of warfarin may be at risk for poor anticoagulation control and adverse events. However, we lack a system to identify patients with the highest dose variability. Our ...

    Authors: Lyndonna Marrast, Mary Evans, Al Ozonoff, Lori E Henault and Adam J Rose
    Citation: Thrombosis Journal 2011 9:14
  44. The ergotamine tartrate associated with certain categories of drugs can lead to critical ischemia of the extremities. Discontinuation of taking ergotamine is usually sufficient for the total regression of isch...

    Authors: Edoardo Cervi, Stefano Bonardelli, Giuseppe Battaglia, Federico Gheza, Roberto Maffeis, Franco Nodari, Roberto Maroldi and Stefano M Giulini
    Citation: Thrombosis Journal 2011 9:13

Official journal of

  • Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.

Annual Journal Metrics

  • 2022 Citation Impact
    3.1 - 2-year Impact Factor
    3.8 - 5-year Impact Factor
    1.011 - SNIP (Source Normalized Impact per Paper)
    0.699 - SJR (SCImago Journal Rank)

    2023 Speed
    10 days submission to first editorial decision for all manuscripts (Median)
    107 days submission to accept (Median)

    2023 Usage 
    708,004 downloads
    943 Altmetric mentions